The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Cannabinoids and Pain: Sites and Mechanisms of Action
Open accessAbstract
The endocannabinoid system, consisting of the cannabinoid1 receptor (CB1R) and cannabinoid2 receptor (CB2R), endogenous cannabinoid ligands (endocannabinoids), and metabolizing enzymes, is present throughout the pain pathways. Endocannabinoids, phytocannabinoids, and synthetic cannabinoid receptor agonists have antinociceptive effects in animal models of acute, inflammatory, and neuropathic pain. CB1R and CB2R located at peripheral, spinal, or supraspinal sites are important targets mediating these antinociceptive effects. The mechanisms underlying the analgesic effects of cannabinoids likely include inhibition of presynaptic neurotransmitter and neuropeptide release, modulation of postsynaptic neuronal excitability, activation of the descending inhibitory pain pathway, and reductions in neuroinflammatory signaling. Strategies to dissociate the psychoactive effects of cannabinoids from their analgesic effects have focused on peripherally restricted CB1R agonists, CB2R agonists, inhibitors of endocannabinoid catabolism or uptake, and modulation of other non-CB1R/non-CB2R targets of cannabinoids including TRPV1, GPR55, and PPARs. The large body of preclinical evidence in support of cannabinoids as potential analgesic agents is supported by clinical studies demonstrating their efficacy across a variety of pain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 4×
“The CB2R has been categorised classically as the peripheral cannabinoid receptor due to its presence on the cells and tissues of the immune, reproductive, cardiovascular, gastrointestinal and respiratory systems and numerous reports which were unable to detect CB2R transcripts in normal healthy brain (Derbenev, Stuart…”
BackgroundInfluentialStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 2×
“…ligands (endocannabinoids) which exert their effects upon binding to these cannabinoid receptors were also discovered, the two best characterised being arachidonyl ethanolamide (anandamide; AEA) (Devane et al., 1992) and 2-arachidonyl glycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995).”
BackgroundDetermination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 20×
“Finn and coworkers have demonstrated that hyperalgesia to intra-plantar formalin injection in WistarKyoto rats that exhibit an anxiodepressive phenotype (versus Sprague-Dawley counterparts) is associated with impaired endocannabinoid-CB1R signalling in the RVM (Rea et al., 2014).”
BackgroundInfluential2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
The amygdala and persistent pain
Neugebauer, V., Li, W., Bird, G. C., & Han, J. S. (2004) · The Neuroscientist · doi:10.1177/1073858403261077 · Cited by 719
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411
Zhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155465 · Cited by 330
Lichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301
Hohmann, A. G., & Herkenham, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00524-7 · Cited by 301
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
Cannabinoid CB1 Receptor Expression in Rat Spinal Cord
Farquhar-Smith, W. P., Egertová, M., Bradbury, E. J., McMahon, S. B., Rice, A. S. C., & Elphick, M. R. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0844 · Cited by 268
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons
Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., & Winter, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.009 · Cited by 251
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats
Petrosino, S., Palazzo, E., de Novellis, V., Bisogno, T., Rossi, F., Maione, S., & Di Marzo, V. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.011 · Cited by 227
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x158066 · Cited by 216
Lynch, M. E., & Ware, M. A. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9600-6 · Cited by 195
Lim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195
Holt, S., Comelli, F., Costa, B., & Fowler, C. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706348 · Cited by 168
Anand, U., Otto, W. R., Sanchez-Herrera, D., Facer, P., Yiangou, Y., Korchev, Y., Birch, R., Benham, C., Bountra, C., Chessell, I. P., et al. (2008) · Pain · doi:10.1016/j.pain.2008.06.007 · Cited by 166 · cited 1×
“…is evidence for expression of CB2R in DRG and in the dorsal horn of the spinal cord and upregulation during neuropathic or 12 inflammatory pain (Anand et al., 2008; Hsieh et al., 2011; Romero-Sandoval & Eisenach, 2007; Romero-Sandoval, Nutile-McMenemy, & DeLeo, 2008; Ross et al., 2001;…”
BackgroundMartin, W. J., Coffin, P. O., Attias, E., Balinsky, M., Tsou, K., & Walker, J. M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01368-7 · Cited by 164
The Enhancement of Morphine Antinociception in Mice by Î9-Tetrahydrocannabinol
Smith, F. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00012-4 · Cited by 146
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139 · cited 7×
“t administration of the CB2R-selective agonists A836339 and AM1241 have been demonstrated in CFA-induced chronic inflammatory pain (Hsieh et al., 2011).”
BackgroundInfluentialKinsey, S. G., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.04.001 · Cited by 118 · cited 1×
“…the contribution of CB1R and/or CB2R for the antiallodynic effects of the FAAH and the MAGL inhibitors in a mouse model of neuropathic pain (Kinsey et al., 2010) and further confirmed that both CB1 and CB2R are necessary for the antiallodynic effects of FAAH inhibitors, while only CB1R are…”
BackgroundCannabinoids modulate pain by multiple mechanisms of action
Richardson, J. D. (2000) · The Journal of Pain · doi:10.1016/s1526-5900(00)90082-8 · Cited by 109
Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain
Siegling, A., Hofmann, H. A., Denzer, D., Mauler, F., & De Vry, J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00798-1 · Cited by 108
de Novellis, V., Vita, D., Gatta, L., Luongo, L., Bellini, G., De Chiaro, M., Marabese, I., Siniscalco, D., Boccella, S., Piscitelli, F., et al. (2011) · Molecular Pain · doi:10.1186/1744-8069-7-7 · Cited by 90 · cited 1×
“…is also associated with increased levels of endovanilloids and endocannabinoids in the medial prefrontal cortex and direct administration of AA-5-HT into 21 the prelimbic and infralimbic cortices reduces nociceptive behaviour in rats following SNI (de Novellis et al., 2011; Giordano et al., 2012).”
BackgroundCosta, B., Colleoni, M., Conti, S., Trovato, A. E., Bianchi, M., Sotgiu, M. L., & Giagnoni, G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705587 · Cited by 89 · cited 1×
“It has been suggested that repeated administration of URB597 may prove to be more efficacious in neuropathic pain models, as observed previously for exogenous cannabinoid receptor agonists (Costa et al., 2004).”
BackgroundManning, B. H., Merin, N. M., Meng, I. D., & Amaral, D. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08238.2001 · Cited by 88
Jhaveri, M. D., Elmes, S. J. R., Richardson, D., Barrett, D. A., Kendall, D. A., Mason, R., & Chapman, V. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06162.x · Cited by 88
La Porta, C., Bura, S. A., Aracil-Fernández, A., Manzanares, J., & Maldonado, R. (2013) · Pain · doi:10.1016/j.pain.2012.10.009 · Cited by 75 · cited 1×
“It had previously been shown that development of mechanical allodynia in this model was unaltered in CB1R and CB2R knockout mice, but attenuated in those overexpressing CB2R, compared with wild-type mice (La Porta et al., 2013).”
ResultWilson, A. R., Maher, L., & Morgan, M. M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.038 · Cited by 52
Cited by
Bonini, S. A., Premoli, M., Tambaro, S., Kumar, A., Maccarinelli, G., Memo, M., & Mastinu, A. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.09.004 · Cited by 669
Yang, S., & Chang, M. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133130 · Cited by 408
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 254
Self-citationCannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Metadata
- Authors
- Starowicz, K., & Finn, D. P.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2017
- Volume
- 80
- Pages
- 437-475
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2674847416
- Cited by
- 193
- References
- 42
- FWCI
- 27.02
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.